메뉴 건너뛰기




Volumn 26, Issue 5, 2010, Pages 541-545

Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: A substudy of the ISS-PART trial

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ZIDOVUDINE;

EID: 77952560260     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0116     Document Type: Article
Times cited : (7)

References (16)
  • 1
    • 33751515147 scopus 로고    scopus 로고
    • CD4+ count guided interruption of antiretroviral treatment
    • El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ count guided interruption of antiretroviral treatment. N Engl J Med 2006;355;2359-2361.
    • (2006) N Engl J Med , vol.355 , pp. 2359-2361
    • El-Sadr, W.M.1    Lundgren, J.D.2    Neaton, J.D.3
  • 2
    • 20144370827 scopus 로고    scopus 로고
    • Interruption of highly active antiretroviral therapy in HIV clinical practice
    • The Italian Cohort of Antiretroviral-Näve Patients Study Group
    • The Italian Cohort of Antiretroviral-Näve Patients Study Group: Interruption of highly active antiretroviral therapy in HIV clinical practice. J Acquir Immune Defic Syndr 2005; 38:407-416.
    • (2005) J Acquir Immune Defic Syndr , vol.38 , pp. 407-416
  • 3
    • 33746713760 scopus 로고    scopus 로고
    • Highly active antiretroviral therapy interruption: Predictors and virologic and immunologic consequences
    • The CASCADE Collaboration
    • The CASCADE Collaboration: Highly active antiretroviral therapy interruption: Predictors and virologic and immunologic consequences. J Acquir Immune Defic Syndr 2006; 42:554-561.
    • (2006) J Acquir Immune Defic Syndr , vol.42 , pp. 554-561
  • 4
    • 56549110656 scopus 로고    scopus 로고
    • Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitorbased regimen
    • Fox Z, Phillips A, Cohen C, et al.: Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitorbased regimen. AIDS 2008;22:2279-2289.
    • (2008) AIDS , vol.22 , pp. 2279-2289
    • Fox, Z.1    Phillips, A.2    Cohen, C.3
  • 5
    • 58749091289 scopus 로고    scopus 로고
    • Two-months-off, fourmonths-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: A randomized trial involving West African adults
    • Danel C, Moh R, Chaix ML, et al.: Two-months-off, fourmonths- on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: A randomized trial involving West African adults. J Infect Dis 2009;199:66-76.
    • (2009) J Infect Dis , vol.199 , pp. 66-76
    • Danel, C.1    Moh, R.2    Chaix, M.L.3
  • 6
    • 34848865063 scopus 로고    scopus 로고
    • Determinants of virologic and immunologic outcomes in chronically HIVinfected subjects undergoing repeated treatment interruptions
    • The Istituto Superiore di Sanità -Pulsed Antiretroviral Therapy (ISS-PART) Study
    • Palmisano L, Giuliano M, Bucciardini R, et al.: Determinants of virologic and immunologic outcomes in chronically HIVinfected subjects undergoing repeated treatment interruptions; The Istituto Superiore di Sanità -Pulsed Antiretroviral Therapy (ISS-PART) Study. J Acquir Immune Defic 2007;46: 39-47.
    • (2007) J Acquir Immune Defic , vol.46 , pp. 39-47
    • Palmisano, L.1    Giuliano, M.2    Bucciardini, R.3
  • 7
    • 0003663974 scopus 로고    scopus 로고
    • CPMP/ICH/281/95. EEC Note for Guidance, London, UK
    • CPMP/ICH/281/95. EEC Note for Guidance, Validation of Analytical Procedures: Methodology. London, UK, 1996. http://www.emea.eu.int/htms/ human(ich/quality/ichfin .htm.
    • (1996) Validation of Analytical Procedures: Methodology
  • 8
    • 0003484310 scopus 로고    scopus 로고
    • U.S. Department of Health and Human Services Food and Drug Administration. U.S. Department of Health and Human Services, Beltsville, MD
    • U.S. Department of Health and Human Services Food and Drug Administration: Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Beltsville, MD, 2001.
    • (2001) Guidance for Industry: Bioanalytical Method Validation
  • 9
    • 59049090776 scopus 로고    scopus 로고
    • Liquid chromatography-electrospray ionization mass spectrometry determination of methylphenidate and ritalinic acid in conventional and non-conventional biological matrices
    • Marchei E, Farré M, Pellegrini M, et al.: Liquid chromatography- electrospray ionization mass spectrometry determination of methylphenidate and ritalinic acid in conventional and non-conventional biological matrices. J Pharm Biomed Anal 2009;49:434-439.
    • (2009) J Pharm Biomed Anal , vol.49 , pp. 434-439
    • Marchei, E.1    Farré, M.2    Pellegrini, M.3
  • 11
    • 31044456584 scopus 로고    scopus 로고
    • Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation
    • An Adult AIDS Clinical Trials Group Study
    • Ribaudo HJ, Haas DW, Tierney C, et al.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006;42:401-407.
    • (2006) Clin Infect Dis , vol.42 , pp. 401-407
    • Ribaudo, H.J.1    Haas, D.W.2    Tierney, C.3
  • 12
    • 2942674438 scopus 로고    scopus 로고
    • Clinical implications of stopping nevirapine-based antiretroviral therapy: Relative pharmacokinetics and avoidance of drug resistance
    • Mackie NE, Fidler S, Tamm N, et al.: Clinical implications of stopping nevirapine-based antiretroviral therapy: Relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004;5:180-184.
    • (2004) HIV Med , vol.5 , pp. 180-184
    • MacKie, N.E.1    Fidler, S.2    Tamm, N.3
  • 13
    • 43249121119 scopus 로고    scopus 로고
    • Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    • Cressey TR, Green H, Khoo S, et al.: Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis 2008;46:1601-1608.
    • (2008) Clin Infect Dis , vol.46 , pp. 1601-1608
    • Cressey, T.R.1    Green, H.2    Khoo, S.3
  • 14
    • 34147106431 scopus 로고    scopus 로고
    • Nevirapine clearance from plasma in African adults stopping therapy: A pharmacokinetic substudy
    • Kikaire B, Khoo S, Walker AS, et al.: Nevirapine clearance from plasma in African adults stopping therapy: A pharmacokinetic substudy. AIDS 2007;21:733-737.
    • (2007) AIDS , vol.21 , pp. 733-737
    • Kikaire, B.1    Khoo, S.2    Walker, A.S.3
  • 15
    • 47549090814 scopus 로고    scopus 로고
    • Detection of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    • Hare CB, Mellors J, Krambrink A, et al.: Detection of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008;47:421-424.
    • (2008) Clin Infect Dis , vol.47 , pp. 421-424
    • Hare, C.B.1    Mellors, J.2    Krambrink, A.3
  • 16
    • 56749132030 scopus 로고    scopus 로고
    • Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption
    • Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, and Martinez-Picado J: Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther 2008;13:945-951.
    • (2008) Antivir Ther , vol.13 , pp. 945-951
    • Darwich, L.1    Esteve, A.2    Ruiz, L.3    Bellido, R.4    Clotet, B.5    Martinez-Picado, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.